Literature DB >> 15792925

Angiotensin II-induced hypertension in mice caused an increase in insulin secretion.

Nana Gletsu1, Thanh N Doan, Justin Cole, Roy L Sutliff, Kenneth E Bernstein.   

Abstract

OBJECTIVE AND
DESIGN: Insulin action was determined in a mouse model of human hypertension via chronic angiotensin II administration followed by a glucose tolerance test.
METHODS: Angiotensin II or saline was infused systemically into mice via osmotic pump for 2 or 4 weeks. In angiotensin II-treated mice versus saline controls we compared blood pressure, blood glucose, and serum insulin concentrations during an intravenous glucose tolerance test and assessed glucose transport and insulin signaling in muscle.
RESULTS: Blood pressure increased at 2 and 4 weeks following angiotensin II treatment. Mice treated with angiotensin II for 4 weeks cleared a glucose bolus faster than mice treated with saline despite similar basal serum insulin concentrations. Upon glucose administration, the increase in serum insulin was greater in angiotensin II-treated mice, 38.8+/-6.5 pmol/l, compared to saline-treated mice, 21.8+/-2.9 pmol/l, but only at 4 weeks of angiotensin II treatment while no difference was observed at 2 weeks of angiotensin II administration. At 4 weeks of angiotensin II treatment, insulin signaling in the liver and in the skeletal muscle was not affected, since both the number of insulin receptors and phosphorylation of Akt were unchanged. Also at 4 weeks of angiotensin II treatment, ex vivo soleus muscle did not exhibit any change in basal and insulin-stimulated glucose uptake.
CONCLUSIONS: This study suggests that long-term angiotensin II treatment for 4 weeks enhances glucose-stimulated insulin secretion in mice. Angiotensin II-induced hyperinsulinemia may play a role in the development of insulin resistance in patients with hypertension.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15792925     DOI: 10.1016/j.vph.2005.01.006

Source DB:  PubMed          Journal:  Vascul Pharmacol        ISSN: 1537-1891            Impact factor:   5.773


  8 in total

Review 1.  Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect?

Authors:  Paul Ernsberger; Richard J Koletsky
Journal:  Curr Opin Pharmacol       Date:  2007-02-15       Impact factor: 5.547

2.  Pharmacologically induced thoracic and abdominal aortic aneurysms in mice.

Authors:  Yasuhisa Kanematsu; Miyuki Kanematsu; Chie Kurihara; Tsung-Ling Tsou; Yoshitsugu Nuki; Elena I Liang; Hiroshi Makino; Tomoki Hashimoto
Journal:  Hypertension       Date:  2010-03-08       Impact factor: 10.190

Review 3.  Metabolic effects of antihypertensive agents: role of sympathoadrenal and renin-angiotensin systems.

Authors:  Paul Ernsberger; Richard J Koletsky
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-06-17       Impact factor: 3.000

4.  Differential Expression of Hypertensive Phenotypes in BXD Mouse Strains in Response to Angiotensin II.

Authors:  Wenyuan Zhao; Tieqiang Zhao; Yuanjian Chen; Syamal K Bhattacharya; Lu Lu; Yao Sun
Journal:  Am J Hypertens       Date:  2017-12-08       Impact factor: 2.689

5.  Evolutionary pathways to SARS-CoV-2 resistance are opened and closed by epistasis acting on ACE2.

Authors:  Gianni M Castiglione; Lingli Zhou; Zhenhua Xu; Zachary Neiman; Chien-Fu Hung; Elia J Duh
Journal:  PLoS Biol       Date:  2021-12-21       Impact factor: 8.029

6.  Endoplasmic Reticulum (ER) Stress in Part Mediates Effects of Angiotensin II in Pancreatic Beta Cells.

Authors:  Latha Ramalingam; Boontharick Sopontammarak; Kalhara R Menikdiwela; Naima Moustaid-Moussa
Journal:  Diabetes Metab Syndr Obes       Date:  2020-08-18       Impact factor: 3.168

7.  Pancreatic AT1aR Deficiency Decreases Insulin Secretion in Obese C57BL/6 Mice.

Authors:  Robin Shoemaker; Yasir AlSiraj; Jeff Chen; Lisa A Cassis
Journal:  Am J Hypertens       Date:  2019-05-09       Impact factor: 2.689

8.  Telotristat ethyl reverses myxomatous changes in mice mitral valves.

Authors:  Xinmei Wang; Danielle Kuban-Johnston; Pablo Lapuerta; Carla M R Lacerda
Journal:  Front Cardiovasc Med       Date:  2022-08-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.